Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study.

PubWeight™: 1.40‹?› | Rank: Top 5%

🔗 View Article (PMID 18328009)

Published in J Womens Health (Larchmt) on April 01, 2008

Authors

Rochelle K Rosen1, Kathleen M Morrow, Alex Carballo-Diéguez, Joanne E Mantell, Susie Hoffman, Fang Gai, Lisa Maslankowski, Wafaa M El-Sadr, Kenneth H Mayer

Author Affiliations

1: The Miriam Hospital, Providence, Rhode Island 02903, USA. Prosen@lifespan.org

Associated clinical trials:

Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women | NCT00705679

Bone Mineral Density Substudy - An Ancillary Study to MTN-003 | NCT00729573

Articles citing this

Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation. AIDS (2010) 2.70

Vaginal drug delivery systems for HIV prevention. AAPS J (2009) 1.51

Rectal microbicides: can we make them and will people use them? AIDS Behav (2011) 1.41

Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Res (2009) 1.30

"Tell Juliana": acceptability of the candidate microbicide VivaGel® and two placebo gels among ethnically diverse, sexually active young women participating in a phase 1 microbicide study. AIDS Behav (2012) 1.11

Clinical evaluation of microbicide formulations. Antiviral Res (2010) 1.05

Designing preclinical perceptibility measures to evaluate topical vaginal gel formulations: relating user sensory perceptions and experiences to formulation properties. AIDS Res Hum Retroviruses (2013) 1.04

Variations in microbicide gel acceptability among young women in the USA and Puerto Rico. Cult Health Sex (2011) 1.04

Covert use, vaginal lubrication, and sexual pleasure: a qualitative study of urban U.S. Women in a vaginal microbicide clinical trial. Arch Sex Behav (2009) 1.02

Engaging male partners in women's microbicide use: evidence from clinical trials and implications for future research and microbicide introduction. J Int AIDS Soc (2014) 0.99

Pre-exposure prophylaxis for the prevention of HIV infection in high risk populations: a meta-analysis of randomized controlled trials. PLoS One (2014) 0.92

Increasing the effectiveness of vaginal microbicides: a biophysical framework to rethink behavioral acceptability. PLoS One (2010) 0.92

Acceptability of Carraguard vaginal microbicide gel among HIV-infected women in Chiang Rai, Thailand. PLoS One (2011) 0.87

Combination HIV prevention interventions: the potential of integrated behavioral and biomedical approaches. Curr HIV/AIDS Rep (2014) 0.86

Perspectives on HIV prevention among urban black women: a potential role for HIV pre-exposure prophylaxis. AIDS Patient Care STDS (2014) 0.85

Sensitive and rapid HPLC quantification of tenofovir from hyaluronic acid-based nanomedicine. AAPS PharmSciTech (2012) 0.84

On-demand microbicide products: design matters. Drug Deliv Transl Res (2017) 0.84

Meaning-making matters in product design: users' sensory perceptions and experience evaluations of long-acting vaginal gels and intravaginal rings. Contraception (2015) 0.83

A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. Expert Opin Investig Drugs (2012) 0.82

Retrocyclin RC-101 blocks HIV-1 transmission across cervical mucosa in an organ culture. J Acquir Immune Defic Syndr (2012) 0.81

Indian married men's interest in microbicide use. AIDS Care (2011) 0.81

Antiviral activity of retrocyclin RC-101, a candidate microbicide against cell-associated HIV-1. AIDS Res Hum Retroviruses (2012) 0.80

Efficacy of Tenofovir 1% Vaginal Gel in Reducing the Risk of HIV-1 and HSV-2 Infection. Clin Med Insights Womens Health (2014) 0.79

Combinations of 3-hydroxyphthalic anhydride-modified ovalbumin with antiretroviral drug-based microbicide candidates display synergistic and complementary effects against HIV-1 infection. J Acquir Immune Defic Syndr (2011) 0.79

Learning from the private sector: towards a keener understanding of the end-user for microbicide introduction planning. J Int AIDS Soc (2014) 0.78

Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides. J Pharm Sci (2014) 0.77

Communication About Microbicide Use Between Couples in KwaZulu-Natal, South Africa. AIDS Behav (2015) 0.76

Perceptibility and the "Choice Experience": User Sensory Perceptions and Experiences Inform Vaginal Prevention Product Design. AIDS Res Hum Retroviruses (2016) 0.75

Assessment of a Microbicide Candidate among a Diverse Cohort of Urban Southern US Women and their Male Sexual Partners. J AIDS Clin Res (2012) 0.75

Optimizing HIV prevention for women: a review of evidence from microbicide studies and considerations for gender-sensitive microbicide introduction. J Int AIDS Soc (2015) 0.75

Psychometric Properties and Validity of a Multi-dimensional Risk Perception Scale Developed in the Context of a Microbicide Acceptability Study. Arch Sex Behav (2015) 0.75

Innovative sensory methods to access acceptability of mixed polymer semisoft ovules for microbicide applications. Drug Deliv Transl Res (2016) 0.75

Articles by these authors

Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17

Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med (2003) 12.23

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis (2005) 10.20

Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med (2006) 9.21

Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med (2012) 6.29

Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr (2009) 5.48

Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med (2011) 5.31

Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med (2008) 5.13

Lessons learned from use of highly active antiretroviral therapy in Africa. Clin Infect Dis (2005) 4.96

Successes and challenges of HIV prevention in men who have sex with men. Lancet (2012) 4.94

Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS (2006) 4.23

In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One (2010) 4.08

Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78

Opt-out testing for human immunodeficiency virus in the United States: progress and challenges. JAMA (2008) 3.61

Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States. J Acquir Immune Defic Syndr (2005) 3.54

Men who have sex with men: perceptions about sexual risk, HIV and sexually transmitted disease testing, and provider communication. Sex Transm Dis (2007) 3.51

Impact of antiretroviral therapy on incidence of pregnancy among HIV-infected women in Sub-Saharan Africa: a cohort study. PLoS Med (2010) 3.27

A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol (2009) 3.26

Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10

When to start ART in Africa--an urgent research priority. N Engl J Med (2013) 3.07

What drives the US and Peruvian HIV epidemics in men who have sex with men (MSM)? PLoS One (2012) 2.97

Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach. PLoS Med (2007) 2.93

Barriers and facilitators to antiretroviral medication adherence among patients with HIV in Chennai, India: a qualitative study. AIDS Patient Care STDS (2005) 2.92

Advanced HIV disease at entry into HIV care and initiation of antiretroviral therapy during 2006-2011: findings from four sub-saharan African countries. Clin Infect Dis (2013) 2.91

Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS (2011) 2.86

Limited Awareness and Low Immediate Uptake of Pre-Exposure Prophylaxis among Men Who Have Sex with Men Using an Internet Social Networking Site. PLoS One (2012) 2.82

A call to action for comprehensive HIV services for men who have sex with men. Lancet (2012) 2.70

HIV risk and the internet: results of the Men's INTernet Sex (MINTS) Study. AIDS Behav (2008) 2.68

Rethinking gender, heterosexual men, and women's vulnerability to HIV/AIDS. Am J Public Health (2010) 2.66

AIDS in America--forgotten but not gone. N Engl J Med (2010) 2.56

Microbicide acceptability research: current approaches and future directions. Soc Sci Med (2005) 2.54

Natural history of human immunodeficiency virus disease in southern India. Clin Infect Dis (2002) 2.39

Correlates of HIV acquisition in a cohort of Black men who have sex with men in the United States: HIV prevention trials network (HPTN) 061. PLoS One (2013) 2.32

Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India. J Acquir Immune Defic Syndr (2006) 2.30

Toward an information-motivation-behavioral skills model of microbicide adherence in clinical trials. AIDS Care (2010) 2.23

Rapid HIV self-testing: long in coming but opportunities beckon. AIDS (2013) 2.22

Data Quality in web-based HIV/AIDS research: Handling Invalid and Suspicious Data. Field methods (2012) 2.20

What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review. Ann Intern Med (2012) 2.19

HIV and STD status among MSM and attitudes about Internet partner notification for STD exposure. Sex Transm Dis (2008) 2.18

High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. Clin Infect Dis (2009) 2.17

Childhood sexual abuse is highly associated with HIV risk-taking behavior and infection among MSM in the EXPLORE Study. J Acquir Immune Defic Syndr (2009) 2.17

Antiretroviral therapy for the prevention of HIV transmission: what will it take? Clin Infect Dis (2014) 2.14

Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. Anal Chem (2008) 2.12

Anal human papillomavirus infection is associated with HIV acquisition in men who have sex with men. AIDS (2009) 2.12

Use of a rapid HIV home test to screen sexual partners: an evaluation of its possible use and relative risk. AIDS Behav (2009) 2.12

Integration of tuberculosis and HIV services in sub-Saharan Africa: lessons learned. Clin Infect Dis (2010) 2.10

Beyond the male condom: the evolution of gender-specific HIV interventions for women. Annu Rev Sex Res (2003) 2.03

The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial. J Womens Health (Larchmt) (2003) 2.03

HIV providers' perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: a qualitative study. AIDS Behav (2014) 2.00

Incidence of immune reconstitution syndrome in HIV/tuberculosis-coinfected patients after initiation of generic antiretroviral therapy in India. J Acquir Immune Defic Syndr (2004) 1.97

Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst (2013) 1.96

Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS (2003) 1.95

The changing natural history of HIV disease: before and after the introduction of generic antiretroviral therapy in southern India. Clin Infect Dis (2005) 1.95

The adolescent and young adult HIV cascade of care in the United States: exaggerated health disparities. AIDS Patient Care STDS (2014) 1.94

Implementation science of pre-exposure prophylaxis: preparing for public use. Curr HIV/AIDS Rep (2010) 1.90

The HIV care continuum: no partial credit given. AIDS (2012) 1.87

Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention. AIDS Patient Care STDS (2012) 1.86

Why reinvent the wheel? Leveraging the lessons of HIV scale-up to confront non-communicable diseases. Glob Public Health (2011) 1.85

First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy. PLoS One (2011) 1.84

Unseen and unheard: predictors of sexual risk behavior and HIV infection among men who have sex with men in Chennai, India. AIDS Educ Prev (2009) 1.83

The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis (2012) 1.80

Sexual mixing patterns and partner characteristics of black MSM in Massachusetts at increased risk for HIV infection and transmission. J Urban Health (2009) 1.79

Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and -uninfected women. Clin Infect Dis (2001) 1.79

Focus on women: linking HIV care and treatment with reproductive health services in the MTCT-Plus Initiative. Reprod Health Matters (2005) 1.77

Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). J Infect Dis (2013) 1.77

Bisexuality, sexual risk taking, and HIV prevalence among men who have sex with men accessing voluntary counseling and testing services in Mumbai, India. J Acquir Immune Defic Syndr (2010) 1.76

The problem of late ART initiation in Sub-Saharan Africa: a transient aspect of scale-up or a long-term phenomenon? J Health Care Poor Underserved (2013) 1.75

Prevention of mother-to-child transmission services as a gateway to family-based human immunodeficiency virus care and treatment in resource-limited settings: rationale and international experiences. Am J Obstet Gynecol (2007) 1.74

HIV/AIDS and the Black Church: what are the barriers to prevention services? J Natl Med Assoc (2005) 1.74

ART adherence, demographic variables and CD4 outcome among HIV-positive patients on antiretroviral therapy in Chennai, India. AIDS Care (2005) 1.73

Total lymphocyte count (TLC) is a useful tool for the timing of opportunistic infection prophylaxis in India and other resource-constrained countries. J Acquir Immune Defic Syndr (2002) 1.71

Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. Lancet (2010) 1.69

Health system and personal barriers resulting in decreased utilization of HIV and STD testing services among at-risk black men who have sex with men in Massachusetts. AIDS Patient Care STDS (2009) 1.69

HIV in Indian MSM: reasons for a concentrated epidemic & strategies for prevention. Indian J Med Res (2011) 1.67

RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses (2012) 1.67

Keeping health facilities safe: one way of strengthening the interaction between disease-specific programmes and health systems. Trop Med Int Health (2010) 1.66

Determination of the underlying cause of death in three multicenter international HIV clinical trials. HIV Clin Trials (2008) 1.65

Nondisclosure of HIV status in a clinical trial setting: antiretroviral drug screening can help distinguish between newly diagnosed and previously diagnosed HIV infection. Clin Infect Dis (2013) 1.64

Assessing motivations to engage in intentional condomless anal intercourse in HIV risk contexts ("Bareback Sex") among men who have sex with men. AIDS Educ Prev (2009) 1.64

Is expanded HIV treatment preventing new infections? Impact of antiretroviral therapy on sexual risk behaviors in the developing world. AIDS (2011) 1.63

Rectal microbicide acceptability: results of a volume escalation trial. Sex Transm Dis (2007) 1.63

Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings. AIDS Patient Care STDS (2011) 1.60

High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health center. J Clin Microbiol (2007) 1.60

HIV acquisition among women from selected areas of the United States: a cohort study. Ann Intern Med (2013) 1.59

Depressive symptoms, utilization of mental health care, substance use and sexual risk among young men who have sex with men in EXPLORE: implications for age-specific interventions. AIDS Behav (2008) 1.59

A survey of MSM HIV prevention outreach workers in Chennai, India. AIDS Educ Prev (2006) 1.58

Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr (2013) 1.57

Highly active antiretroviral therapy does not completely suppress HIV in semen of sexually active HIV-infected men who have sex with men. AIDS (2012) 1.56

Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis (2007) 1.56

Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clin Infect Dis (2010) 1.55

Prospective associations between HIV-related stigma, transmission risk behaviors, and adverse mental health outcomes in men who have sex with men. Ann Behav Med (2011) 1.55

Emergency department patient acceptance of opt-in, universal, rapid HIV screening. Public Health Rep (2009) 1.54

Contact with HIV prevention programmes & willingness for new interventions among truckers in India. Indian J Med Res (2013) 1.51

Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. AIDS (2006) 1.51

Age-related prevalence of anal cancer precursors in homosexual men: the EXPLORE study. J Natl Cancer Inst (2005) 1.50